Artificial selection

Artificial intelligence subsidiaries of RadNet, DeepHealth and

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and LOS ANGELES, May 16, 2022 (GLOBE NEWSWIRE) — RadNet, Inc., (NASDAQ: RDNT) today announced that it has received FDA clearances for its DeepHealth Saige-DX™ mammography and quantib® Artificial Intelligence (“AI”) Algorithms Prostate 2.0 MRI.

Saige-DX: AI mammography diagnostic software

Saige-Dx, a more advanced successor to our FDA-approved Saige-Q worklist triage software, is a cancer detection tool that allows radiologists to more effectively detect the presence or absence of breast cancer through the use of artificial intelligence. DeepHealth’s powerful new AI technology automatically identifies suspicious lesions in mammograms and assigns a level of suspicion to each finding and the entire case. It helps detect and diagnose breast cancer earlier while reducing unnecessary callbacks.

“In our study to support FDA clearance, all 18 radiologists who participated showed improved performance when using Saige-Dx, resulting in the greatest increase in performance of any product in the market. Mammography AI on the Market Today. The improved performance resulted in both an increase in the percentage of cancers detected and a decrease in the false positive rate when using Saige-Dx,” said Bill Lotter, Ph.D., CTO and co-founder of DeepHealth.

“Saige-Dx is built on our advanced deep learning algorithms. Our highly accurate AI, as described in a natural medicine last year’s paper, showed the ability to detect cancer one to two years earlier than fellow-trained breast imaging radiologists. The approval of Saige-Dx represents another step forward in the advancement of cancer care. Feedback from physicians who have worked with our software tools has been overwhelmingly positive, making them more accurate and efficient in interpreting mammography images,” said Gregory Sorensen, MD, CEO and co-founder of DeepHealth.

quantib® Prostate 2.0: an AI-powered solution for prostate MRI reading and reporting

quantib® Prostate is an AI-based software solution that advances the prostate MRI reporting workflow and is accessible directly from the radiologist’s reading station. The solution comes with a suite of tools to improve reporting quality and speed, including AI-based segmentations and volumetrics, PSA density calculation, accurate registration and motion correction, one-click segmentation of lesion candidates, support for PI-RADS scoring and standardized reporting. to facilitate a simple and complete communication of the results. FDA 510k Special Clearance has been granted for a major solution upgrade (from version 1.3) which now includes fully automatic prostate area segmentation (in addition to prostate segmentation) and automated initiation of lesion localization on the PI-RADS sector map.

“We are thrilled to present this update to Quantib® Prostate, including a selection of new features requested by our customers over the past few months. We seek to continually improve our software to help radiologists and urologists in the best possible way, and we provide updated solutions to our customers as quickly as possible,” said Arthur Post Uiterweer, CEO of Quantib.

Dr. Howard Berger, President and CEO of RadNet, said, “We are very proud that two of our subsidiaries, DeepHealth and Quantib, have received FDA clearance for their lead products. Artificial intelligence will have a transformative impact on radiology and cancer. care, and we are committed to delivering these advances to patients and healthcare providers. These recent approvals will help us improve patient outcomes while reducing costs. The Biden administration, through its Cancer Moonshot program, is committed to dramatically reducing cancer death rates. We believe these AI tools will play an important role in the early detection and diagnosis of cancer, which which will result in improved survival rates and better patient outcomes.

About RadNet, Inc.

RadNet, Inc. is the leading national provider of fixed-site, stand-alone diagnostic imaging services in the United States based on number of locations and annual imaging revenues. RadNet has a network of 351 owned and/or operated Ambulatory Imaging Centers. RadNet markets include Arizona, California, Delaware, Florida, Maryland, New Jersey and New York. Together with affiliated radiologists, and including full-time and per diem employees and technicians, RadNet has a total of approximately 9,000 employees. For more information, visit

About DeepHealth, Inc.

DeepHealth, a wholly owned subsidiary of RadNet, Inc., uses machine learning to distill knowledge from medical experts into software to help physicians. DeepHealth’s mission is to enable the best care by providing products that clinicians and patients can trust, through rigorous science and clinical integration. DeepHealth offers two FDA cleared solutions focused on improving the accuracy and efficiency of mammogram interpretation. For more information, visit

About Quantib

Quantib, a wholly owned subsidiary of RadNet, Inc., provides AI radiology solutions to enable faster and more accurate diagnosis by quickly identifying abnormalities, supporting adequate and timely patient care. Using state-of-the-art artificial intelligence technology, Quantib’s software advances the diagnostic pathway by providing FDA cleared and CE marked solutions related to neurodegeneration and prostate cancer. All solutions are deployed through the Quantib AI Node platform, enabling seamless workflow integration and rapid regulatory clearance.

Forward-looking statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements express our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections and anticipated future conditions, events and trends. Forward-looking statements can generally be identified by words such as: “anticipate”, “intend”, “plan”, “objective”, “seek”, “believe”, “project”, “estimate”, ” expect”, “strategy”, “future”, “probable”, “may”, “should”, “will” and similar references to future periods.

Forward-looking statements are neither historical facts nor guarantees of future performance. Because forward-looking statements relate to the future, they are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict and many of which are beyond our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Accordingly, you should not place undue reliance on any of these forward-looking statements.

Media contact – DeepHealth, Inc.:
Bret Baird
Commercial director
[email protected]

Media contact – Quantib BV:
Ory Six
Marketing director
+0031 10 841 1749
[email protected]

Media Contact – RadNet, Inc.:
Mark Stolper
Executive Vice President and Chief Financial Officer